A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF HEDGEHOG (HH) PATHWAY INHIBITOR GDC-0449 AS MAINTENANCE THERAPY IN PATIENTS WITH OVARIAN CANCER IN 2(ND) OR 3(RD) COMPLETE REMISSION (CR) Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Kaye, S. B., Fehrenbacher, L., Holloway, R., Horowitz, N., Karlan, B., Amit, A., Slomovitz, B., Chang, I., Yauch, R. L., Reddy, J. C.

authors

Publication Date

  • October 1, 2010

webpage

published in

category

start page

  • 11

end page

  • 11

volume

  • 21

WoS Citations

  • 3

WoS References

  • 0